2-[[2-[1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]ethylamino]methyl]aniline | 1026376-96-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-[[2-[1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]ethylamino]methyl]aniline
• CAS: 1026376-96-4
• 化学式: C₂₃H₃₁N₃O₂
• 分子量: 381.518
• InChiKey: QEBGBRJSBSUSNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  59.8
• 氢给体数：
  2
• 氢受体数：
  5

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	2-[1-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]-N-[(2-nitrophenyl)methyl]ethanamine	1026057-38-4	C23H29N3O4	411.501
  ——	2-[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]-2-ethylamine	194612-31-2	C16H24N2O2	276.379
  ——	[1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl]acetonitrile	194612-30-1	C16H20N2O2	272.347

反应信息

• 作为反应物：
  描述：

  尿素 、 2-[[2-[1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]ethylamino]methyl]aniline 反应 2.0h， 生成 3-{2-[1-(2,3-Dihydro-benzo[1,4]dioxin-2-ylmethyl)-piperidin-4-yl]-ethyl}-3,4-dihydro-1H-quinazolin-2-one
  参考文献：
  名称：

  New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity

  摘要：

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.

  DOI：

  10.1021/jm991121g
• 作为产物：
  描述：

  2-(1-苄基-4-哌啶)乙腈 在 盐酸 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 铁粉 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 23.0h， 生成 2-[[2-[1-(2,3-Dihydro-1,4-benzodioxin-3-ylmethyl)piperidin-4-yl]ethylamino]methyl]aniline
  参考文献：
  名称：

  New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity

  摘要：

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.

  DOI：

  10.1021/jm991121g

文献信息

• New Substituted 1-(2,3-Dihydrobenzo[1,4]dioxin-2-ylmethyl)piperidin-4-yl Derivatives with α₂-Adrenoceptor Antagonist Activity
  作者：Patrice Mayer、Pascale Brunel、Céline Chaplain、Christel Piedecoq、Francis Calmel、Philippe Schambel、Philippe Chopin、Thierry Wurch、Petrus J. Pauwels、Marc Marien、Jean-Louis Vidaluc、Thierry Imbert

  DOI：10.1021/jm991121g

  日期：2000.10.1

  The emergence of a novel theory concerning the role of noradrenaline in the progression and the treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases has provided a new impetus toward the discovery of novel compounds acting at alpha(2)-adrenoceptors. A series of substituted 1-(2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl) piperidin-4-yl derivatives bearing an amide, urea, or imidazolidinone moiety was studied. Some members of this series of compounds proved to be potent alpha(2)-adrenoceptor antagonists with good selectivity versus alpha(1)-adrenergic and D(2)-dopamine receptors. Particular emphasis is given to compound 33g which displays potent alpha(2)-adrenoceptor binding affinity in vitro and central effects in vivo following oral administration.